ONCODESIGN Logo

ONCODESIGN

ALONC | PA

Overview

Corporate Details

ISIN(s):
FR0011766229
LEI:
9695004HPDBVG72O8851
Country:
France
Address:
20 RUE JEAN MAZEN, 21000 DIJON
Sector:
Health Care
Industry:
Biotechnology

Description

Founded in 1995 by Dr Philippe Genne, the Company’s CEO and Chairman, Oncodesign is a biopharma company dedicated to the precision medicine. With its unique experience acquired by working with more than 600 clients, including the world’s largest pharmaceutical companies, along with its comprehensive technological platform combining state-of-the-art medicinal chemistry, pharmacology, regulated bioanalysis and medical imaging, Oncodesign is able to predict and identify, at a very early stage, each molecule's therapeutic usefulness and potential to become an effective drug. Applied to kinase inhibitors, which represent a market estimated at over $46 billion in 2016 and accounting for almost 25% of the pharmaceutical industry’s R&D expenditure, Oncodesign’s technology has already enabled the targeting of several promising molecules with substantial therapeutic potential, in oncology and elsewhere, along with partnerships with pharmaceutical groups such as Bristol-Myers Squibb and UCB

Social Media

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2022-12-13 14:25
Takeover Announcement Report
Communiqués publiés en période d'offre publique d'acquisition / OPA Autres comm…
French 150.7 KB
2022-12-13 11:17
Regulatory News Service
Franchissement de seuils
French 209.0 KB
2022-11-24 08:00
Takeover Announcement Report
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 145.1 KB
2022-11-23 17:37
Takeover Announcement Report
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 724.9 KB
2022-11-23 17:36
Takeover Announcement Report
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 2.3 MB
2022-11-08 16:38
Takeover Announcement Report
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 2.2 MB
2022-11-08 15:54
Takeover Announcement Report
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 231.6 KB
2022-11-02 17:28
Takeover Announcement Report
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 1.0 MB
2022-11-02 17:25
Takeover Announcement Report
Communiqués publiés en période d'offre publique d'acquisition / OPA Modalités d…
French 506.0 KB
2022-10-26 11:17
Regulatory News Service
Franchissement de seuil
French 198.3 KB
2022-10-26 11:16
Regulatory News Service
Franchissement de seuils
French 206.0 KB
2022-10-19 08:00
Inside Information Statement
Inside Information / Operations of the issuer (acquisitions, sales...)
English 340.5 KB
2022-10-19 08:00
Inside Information Statement
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
French 390.8 KB
2022-10-04 18:00
Inside Information Statement
Inside Information / Other news releases
English 268.6 KB
2022-10-04 18:00
Inside Information Statement
Informations privilégiées / Autres communiqués
French 273.9 KB

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo 1NKEMIA Spain IKM
2cureX AB Logo 2cureX AB Sweden 2CUREX
4SC AG Logo 4SC AG Germany VSC
Abera Bioscience AB Logo Abera Bioscience AB Sweden ABERA
ABIONYX Pharma Logo ABIONYX Pharma France ABNX
Abliva Logo Abliva Sweden ABLI
AB Science Logo AB Science France AB
Acticor Biotech Logo Acticor Biotech France ALACT
Active Biotech Logo Active Biotech Sweden ACTI
AcuCort AB Logo AcuCort AB Sweden ACUC